Akero Therapeutics, Inc. — Director's Dealing 2019

Jun 20, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2019-06-19

Reporting Person: Iwicki Mark T (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.61	2028-10-17	Common Stock (76227)		Direct
Stock Option (Right to Buy)	$6.36	2029-01-15	Common Stock (11493)		Direct
Stock Option (Right to Buy)	$7.01	2029-04-25	Common Stock (70587)		Direct

Footnotes

F1: 25% of this option shall vest on October 1, 2019, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.

F2: 25% of this option shall vest on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.